IDH1 inhibitor amplified the efficiency of glioma-associated antigens vaccination, augmented the infiltration of CD8 + T cell and improved the survival of mice challenged with IDH1mt tumor (Kohanbash et al., 2017). This evidence concerns the gene IDH1 and central nervous system cancer.